دورية أكاديمية
أعرض في EDS

Host cell-dependent late entry step as determinant of hepatitis B virus infection.

التفاصيل البيبلوغرافية
العنوان: Host cell-dependent late entry step as determinant of hepatitis B virus infection.
المؤلفون: Hong X; Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America., Kawasawa YI; Department of Pharmacology, Department of Biochemistry and Molecular Biology, Institute for Personalized Medicine, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America., Menne S; Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, District of Columbia, United States of America., Hu J; Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America.
المصدر: PLoS pathogens [PLoS Pathog] 2022 Jun 17; Vol. 18 (6), pp. e1010633. Date of Electronic Publication: 2022 Jun 17 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: Hepatitis B* , Hepatitis B Virus, Woodchuck*, Animals ; DNA, Circular/metabolism ; DNA, Viral/genetics ; DNA, Viral/metabolism ; Hepatitis B virus/metabolism ; Hepatitis Delta Virus/genetics ; Hepatitis Delta Virus/metabolism ; Hepatocytes ; Humans ; Marmota ; Virus Replication/genetics
مستخلص: Hepatitis B virus (HBV) has a highly restricted host range and cell tropism. Other than the human sodium taurocholate cotransporting polypeptide (huNTCP), the HBV entry receptor, host determinants of HBV susceptibility are poorly understood. Woodchucks are naturally infected with woodchuck hepatitis virus (WHV), closely related to HBV, but not with HBV. Here, we investigated the capabilities of woodchuck hepatic and human non-hepatic cell lines to support HBV infection. DNA transfection assays indicated that all cells tested supported both HBV and WHV replication steps post entry, including the viral covalently closed circular DNA (cccDNA) formation, which is essential for establishing and sustaining infection. Ectopic expression of huNTCP rendered one, but not the other, woodchuck hepatic cell line and the non-hepatic human cell line competent to support productive HBV entry, defined here by cccDNA formation during de novo infection. All huNTCP-expressing cell lines tested became susceptible to infection with hepatitis D virus (HDV) that shares the same entry receptor and initial steps of entry with HBV, suggesting that a late entry/trafficking step(s) of HBV infection was defective in one of the two woodchuck cell lines. In addition, the non-susceptible woodchuck hepatic cell line became susceptible to HBV after fusion with human hepatic cells, suggesting the lack of a host cell-dependent factor(s) in these cells. Comparative transcriptomic analysis of the two woodchuck cell lines revealed widespread differences in gene expression in multiple biological processes that may contribute to HBV infection. In conclusion, other than huNTCP, neither human- nor hepatocyte-specific factors are essential for productive HBV entry. Furthermore, a late trafficking step(s) during HBV infection, following the shared entry steps with HDV and before cccDNA formation, is subject to host cell regulation and thus, a host determinant of HBV infection.
Competing Interests: The authors have declared that no competing interests exists.
References: World J Gastroenterol. 2007 Jan 7;13(1):104-24. (PMID: 17206759)
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1841-6. (PMID: 11172038)
J Virol. 2022 Jan 12;96(1):e0130521. (PMID: 34643434)
J Virol. 1995 Oct;69(10):6158-69. (PMID: 7666518)
J Virol. 2007 Jun;81(12):6164-74. (PMID: 17409153)
Hepatology. 2012 Sep;56(3):820-30. (PMID: 22431061)
J Virol. 2021 Jan 13;95(3):. (PMID: 33148795)
J Virol. 2018 Mar 28;92(8):. (PMID: 29437960)
Mol Ther. 2016 Apr;24(4):671-7. (PMID: 26916283)
J Virol. 2013 Jun;87(11):6415-27. (PMID: 23536683)
J Virol. 2015 Sep;89(17):9021-8. (PMID: 26085156)
Cold Spring Harb Perspect Med. 2015 Jul 01;5(7):a021386. (PMID: 26134841)
J Virol. 2018 Jun 29;92(14):. (PMID: 29743374)
J Virol. 2020 Dec 9;95(1):. (PMID: 33055252)
J Virol. 1995 Dec;69(12):7593-600. (PMID: 7494266)
Sci Rep. 2021 Oct 5;11(1):19799. (PMID: 34611272)
PLoS Pathog. 2017 Sep 25;13(9):e1006658. (PMID: 28945802)
Hepatology. 2017 Dec;66(6):2066-2077. (PMID: 28833361)
Hepatology. 2017 Nov;66(5):1662-1674. (PMID: 28640507)
J Gen Virol. 1988 Jul;69 ( Pt 7):1591-9. (PMID: 2839596)
J Virol. 2018 Nov 12;92(23):. (PMID: 30232184)
Mol Ther Nucleic Acids. 2014 Dec 16;3:e216. (PMID: 25514649)
PLoS Pathog. 2010 Sep 02;6(9):e1001082. (PMID: 20824087)
G3 (Bethesda). 2019 Dec 3;9(12):3943-3952. (PMID: 31645421)
J Virol. 2007 Sep;81(18):10072-80. (PMID: 17609269)
J Virol. 2019 Sep 30;93(20):. (PMID: 31375584)
Cell Mol Immunol. 2014 Mar;11(2):175-83. (PMID: 24509445)
Elife. 2012 Nov 13;1:e00049. (PMID: 23150796)
Hepatology. 1987 Sep-Oct;7(5):937-40. (PMID: 2888713)
J Virol. 2005 Aug;79(15):9369-80. (PMID: 16014900)
Virology. 2017 May;505:1-11. (PMID: 28213271)
J Virol. 2018 Nov 12;92(23):. (PMID: 30232183)
J Virol. 2016 Aug 26;90(18):8302-13. (PMID: 27384660)
Gastroenterology. 2014 Apr;146(4):1070-83. (PMID: 24361467)
J Virol. 2017 Aug 10;91(17):. (PMID: 28637752)
Hepatology. 2017 Sep;66(3):703-716. (PMID: 28195359)
Hepatology. 2021 Jul;74(1):99-115. (PMID: 33458844)
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8487-8492. (PMID: 30952782)
J Virol. 2001 Mar;75(6):2900-11. (PMID: 11222715)
J Virol. 2015 Mar;89(5):2918-30. (PMID: 25540387)
J Virol. 2002 Apr;76(8):3819-27. (PMID: 11907222)
J Hepatol. 2019 Aug;71(2):289-300. (PMID: 31077792)
Antiviral Res. 2020 Oct;182:104898. (PMID: 32758525)
J Infect Dis. 1987 Oct;156(4):622-9. (PMID: 2442271)
Gastroenterology. 2019 Jan;156(2):338-354. (PMID: 30243619)
Proc Natl Acad Sci U S A. 1978 Sep;75(9):4533-7. (PMID: 212758)
PLoS Pathog. 2015 Apr 22;11(4):e1004840. (PMID: 25902143)
Nat Commun. 2017 Dec 15;8(1):2146. (PMID: 29247188)
J Hepatol. 2016 Mar;64(3):556-64. (PMID: 26576481)
F1000Res. 2020 Sep 16;9:1137. (PMID: 33274050)
J Virol. 2021 May 24;95(12):. (PMID: 33789995)
J Virol. 1996 Oct;70(10):7085-91. (PMID: 8794354)
J Virol. 2008 Aug;82(15):7276-83. (PMID: 18495772)
J Virol. 2013 Jun;87(12):6931-42. (PMID: 23576513)
J Virol. 2007 Nov;81(22):12472-84. (PMID: 17804499)
Virology. 1997 Mar 3;229(1):25-35. (PMID: 9123867)
J Virol. 2013 Jul;87(14):7977-91. (PMID: 23678176)
PLoS Pathog. 2020 Mar 30;16(3):e1008459. (PMID: 32226051)
PLoS Pathog. 2021 Jan 25;17(1):e1009230. (PMID: 33493210)
Emerg Microbes Infect. 2021 Dec;10(1):852-864. (PMID: 33870849)
J Virol. 2016 Apr 14;90(9):4827-4831. (PMID: 26865711)
Hepatology. 2012 Jul;56(1):76-85. (PMID: 22334419)
PLoS One. 2015 Jun 16;10(6):e0128401. (PMID: 26079492)
Hepatology. 2017 Dec;66(6):1779-1793. (PMID: 28665004)
Antiviral Res. 2019 Mar;163:11-18. (PMID: 30639437)
معلومات مُعتمدة: R37 AI043453 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (DNA, Circular)
0 (DNA, Viral)
تواريخ الأحداث: Date Created: 20220617 Date Completed: 20220704 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9246237
DOI: 10.1371/journal.ppat.1010633
PMID: 35714170
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1010633